New Osteoporosis Drugs in the Works
Biologic Osteoporosis Drugs Denosumab and Odanacatib Show Promise in Clinical Trials
WebMD News Archive
Sept. 18, 2008 -- Two experimental osteoporosis drugs are getting attention from bone experts -- and
may become the first biologic drugs to treat osteoporosis.
The drugs are called denosumab and odancatib. Results from their latest
clinical trials, presented this week in Montreal at the annual meeting of the
American Society for Bone and Mineral Research, show that the drugs boosted
bone mineral density in postemenopausal women with osteoporosis.
Denosumab and odanacatib are "totally, completely new" ways of
approaching osteoporosis, says Susan Bukata, MD, an orthopaedic surgeon and
associate professor who directs the University of Rochester's Center for Bone
"This is the new frontier in osteoporosis. This is the step into
biologics for osteoporosis treatment,"
Bukata tells WebMD. She predicts that denosumab or odanacatib probably won't be
the first osteoporosis treatments that doctors prescribe for most patients, and
she says cost may be a factor in how widely the new drugs get used, if approved
by the FDA.
How the New Drugs Work
Denosumab and odanacatib are both biologic drugs that target osteoclasts,
which are cells that tear down bone to make way for new bone.
Your bones don't just sit there; they're constantly being remodeled.
Osteoclasts are the wrecking crew; other cells, called osteoblasts, are the
After you reach peak bone mass at about age 30, the balance between the bone
breakdown and bone buildup shifts, favoring bone loss. Age -- and, for women,
menopause -- tilts the balance further toward bone loss. In osteoporosis, the
bones have become dangerously weak.
"As you age, things slow down," Bukata explains. "Unfortunately,
for a lot of people, bone-building capacity slows down a little bit more than
their bone-loss capacity."
The basic idea behind the new osteoporosis drugs is to rebalance bone loss
and bone building so that those two processes "either stay in balance or,
in fact, allow the osteoblasts to catch up a little bit," says Bukata.
"By adding these agents, we are able to push things the way a younger
person manages bone."
Denosumab's Clinical Trial
Denosumab is a monoclonal antibody given by injection twice a year. It
targets a protein called RANK ligand, which osteoclasts need to do their
Denosumab has finished its phase lll clinical trials, the last set of trials
needed before submitting a drug to the FDA for approval.
In those trials, postmenopausal women with low bone mineral density either
got a shot of denosumab every six months or took alendronate (the active
ingredient in Fosamax) every week.
A year later, bone mineral density in the lumbar spine and in the hip had
improved more for the denosumab group than for the alendronate group.
Bukata notes that because biologic drugs affect the immune system,
researchers keep a close eye on infection rates for biologic drugs, but
infections weren't more common with denosumab in the trial.